Date |
Product |
Disease |
Phase |
Company |
Therapeutic area |
2016-06-11
|
ToleraCyte™ (programmed CD34+ immuno-regulatory cell product) |
|
preclinical |
Fate Therapeutics (USA - CA) |
Autoimmune diseases |
2016-06-10
|
Kalydeco® (ivacaftor) |
cystic fibrosis |
|
Vertex Pharmaceuticals (USA - MA) |
Rare diseases - Genetic diseases |
2016-06-10
|
CHS-0214 (investigational etanercept biosimilar) |
rheumatoid arthritis |
3 |
Coherus BioSciences (USA - CA) Daiichi Sankyo (Japan) Baxalta (USA - IL) |
Autoimmune diseases – Inflammatory diseases - Rheumatic diseases |
2016-06-09
|
baricitinib (LY3009104) |
rheumatoid arthritis |
3 |
Eli Lilly (USA - IN) Incyte Corporation (USA - DE) |
Autoimmune diseases – Inflammatory diseases - Rheumatic diseases |
2016-06-09
|
olaratumab |
advanced soft tissue sarcoma (STS) not amenable to curative treatment with radiotherapy or surgery |
1b/2 |
Eli Lilly (USA - IN) |
Cancer - Oncology |
2016-06-09
|
ALN-TTRsc02 |
transthyretin-mediated amyloidosis (ATTR amyloidosis) |
1 |
Alnylam Pharmaceuticals (USA - MA) |
Rare diseases - Genetic diseases |
2016-06-08
|
M923, a biosimilar version of Humira® (adalimumab) |
|
1 |
Momenta Pharmaceuticals (USA - MA) Baxalta (USA - IL) |
Autoimmune diseases – Inflammatory diseases |
2016-06-08
|
AMG 334 (erenumab) |
prevention of episodic migraine |
2 |
Amgen (USA - CA) Novartis (Switzerland) |
CNS diseases |
2016-06-07
|
ublituximab and TGR-1202 |
diffuse large B-cell lymphoma (DLBCL) |
2b |
TG Therapeutics (USA - NY) |
Cancer - Oncology |
2016-06-07
|
opicinumab (anti-LINGO-1 - BIIB033) |
relapsing multiple sclerosis |
2 |
Biogen (USA - MA) |
Neurodegenerative diseases |
2016-06-07
|
ICT-107 with maintenance temozolomide |
glioblastoma |
3 |
ImmunoCellular Therapeutics (USA - CA) |
Cancer - Oncology - Rare diseases |
2016-06-07
|
BGB324 and erlotinib |
non-small cell lung cancer |
1-2 |
BergenBio (Norway) |
Cancer - Oncology |
2016-06-07
|
IFX-1 |
patients undergoing complex cardiac surgery |
2 |
InflaRx (Germany) |
Cardiovascular diseases |
2016-06-06
|
sacituzumab govitecan - IMMU-132 |
metastatic non-small-cell lung cancer (NSCLC), |
2 |
Immunomedics (USA - NJ) |
Cancer - Oncology |
2016-06-06
|
sacituzumab govitecan - IMMU-132 |
metastatic small-cell lung cancer (SCLC) |
2 |
Immunomedics (USA - NJ) |
Cancer - Oncology |
2016-06-06
|
aramchol |
NASH (non-alcoholic steatohepatitis) |
2b |
Galmed Pharmaceuticals (Israel) |
Hepatic diseases - Liver diseases |
2016-06-06
|
MOR202 (antiCD38 antibody) |
relapsed or refractory multiple myeloma |
1-2a |
MorphoSys (Germany) |
Cancer - Oncology - Rare diseases |
2016-06-06
|
dupilumab |
moderate-to-severe atopic dermatitis |
3 |
Sanofi (France) Regeneron Pharmaceuticals (USA - NY) |
Dermatological diseases - Inflammatory diseases |
2016-06-06
|
MSB0010718C (avelumab) |
metastatic Merkel cell carcinoma |
2 |
Merck Serono (Germany) Pfizer (USA - NY) |
Cancer - Oncology |
2016-06-06
|
seliciclib and sapacitabine |
advanced solid tumors |
1 |
Cyclacel Pharmaceuticals (USA - NJ) |
Cancer - Oncology |